IL6R and Parkinson disease: Nevertheless, our study reveals the contribution of glia-related neuroinflammatory responses to the pathophysiology of PD and indicates the blockade/neutralization of IL-6R antibodies as a possible and valid therapeutic strategy to prevent, slow down, or possibly halt PD pathogenesis.